Notice: Memcache::get() [memcache.get]: Server 192.168.72.130 (tcp 11212) failed with: Connection refused (111) in /www/sites/www.stockpickr.com/docroot/sites/all/modules/contrib/memcache/dmemcache.inc on line 107

Notice: Memcache::get() [memcache.get]: Server 192.168.70.85 (tcp 11212) failed with: Connection refused (111) in /www/sites/www.stockpickr.com/docroot/sites/all/modules/contrib/memcache/dmemcache.inc on line 107
HPTX Stock Quote - Hyperion Therapeutics Inc Stock Price and Data - Stockpickr!
Health Care: Drugs

Hyperion Therapeutics Inc (HPTX: NASDAQ)

$25.4 0.18 | 0.71%
10/01/14 - 04:00 PM ET
Company Profile
Price and Volume
Recent Price 25.22
52 Week High 32.98
52 Week Low 18.97
Avg. Daily Vol. (Mil) 0.12
Beta (3 year) 0.89
Share Related Items
Mkt Cap (Mil) 519.48
Shares Out (Mil) 20.60
Float (Mil) 9.71
Dividend Information
Yield % 0.00
Annual Dividend 0.00
Payout Ratio 0.00
Financial Strength
Quick Ratio 3.30
Current Ratio 3.40
LT Debt/ Equity 0.00
Total Debt / Equity 0.04
Valuation Ratios
Price Earnings 28.50
Price/Sales 5.73
Price/Book 3.45
Price/Cash Flow 20.60
Per Share Data
Earnings 0.89
Sales 4.40
Book Value 7.32
Cash Flow 1.22
Business Summary
Hyperion Therapeutics Inc is a commercial-stage biopharmaceutical company that is engaged into the development and commercialization of novel therapeutics to treat disorders in the areas of orphan diseases and hepatology.
General Information
2000 Sierra Point Parkway
Suite 400
Brisbane, CA 94005
www.hyperiontx.com
Industry : Drugs
Sector: Health Care
Employees: 54
CEO: Donald J. Santel
Short Interest
Current Month (Mil) 0.78
Previous Month (Mil) 0.72
Short Interest Ratio (Days) 7.10
Management Effectiveness
Return on Equity 12.80
Return on Assets 6.40
Return on Investments 12.80
Profitability
Gross Margin 87.30
EBIT Margin 20.60
Profit Margin 21.30

Portfolios with HPTX

Latest HPTX Headlines from TheStreet

More Financial News for HPTX

Press Releases for HPTX

See All Press Releases
brokerage partners
connect with Stockpickr
Fan us on FaceBook
Follow us on Twitter